AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
Overall FOLD gets a fundamental rating of 4 out of 10. We evaluated FOLD against 557 industry peers in the Biotechnology industry. FOLD has an average financial health and profitability rating. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
In the past year FOLD had a positive cash flow from operations.
In the past 5 years FOLD always reported negative net income.
FOLD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FOLD has a Return On Assets of -3.72%. This is amongst the best in the industry. FOLD outperforms 87.97% of its industry peers.
The Return On Equity of FOLD (-15.18%) is better than 87.25% of its industry peers.
The Return On Invested Capital of FOLD (5.93%) is better than 93.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROIC | 5.93% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 8.80%, FOLD belongs to the top of the industry, outperforming 93.54% of the companies in the same industry.
Looking at the Gross Margin, with a value of 90.60%, FOLD belongs to the top of the industry, outperforming 92.82% of the companies in the same industry.
FOLD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
The number of shares outstanding for FOLD has been increased compared to 1 year ago.
FOLD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FOLD has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.51, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
FOLD's Altman-Z score of -1.51 is in line compared to the rest of the industry. FOLD outperforms 55.48% of its industry peers.
The Debt to FCF ratio of FOLD is 242.98, which is on the high side as it means it would take FOLD, 242.98 years of fcf income to pay off all of its debts.
FOLD has a Debt to FCF ratio of 242.98. This is amongst the best in the industry. FOLD outperforms 90.84% of its industry peers.
A Debt/Equity ratio of 2.02 is on the high side and indicates that FOLD has dependencies on debt financing.
FOLD has a Debt to Equity ratio of 2.02. This is amonst the worse of the industry: FOLD underperforms 80.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Altman-Z | -1.51 |
ROIC/WACC0.54
WACC10.89%
2.3 Liquidity
A Current Ratio of 3.34 indicates that FOLD has no problem at all paying its short term obligations.
With a Current ratio value of 3.34, FOLD is not doing good in the industry: 60.86% of the companies in the same industry are doing better.
FOLD has a Quick Ratio of 2.47. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FOLD (2.47) is worse than 67.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.63%, which is quite impressive.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.26%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
3.2 Future
FOLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 76.15% yearly.
The Revenue is expected to grow by 19.94% on average over the next years. This is quite good.
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue Next Year17.78%
Revenue Next 2Y20.45%
Revenue Next 3Y20.92%
Revenue Next 5Y19.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 23.16, which indicates a rather expensive current valuation of FOLD.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 91.74% of the companies in the same industry.
FOLD's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.16 |
4.2 Price Multiples
92.46% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
FOLD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FOLD is cheaper than 90.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1166.23 | ||
| EV/EBITDA | 35.9 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 79.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.03%
EPS Next 3Y79.24%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.09
-0.21 (-3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.99%
Inst Owner Change0%
Ins Owners0.6%
Ins Owner Change5.79%
Market Cap1.88B
Analysts82.22
Price Target15.98 (162.4%)
Short Float %7.41%
Short Ratio3.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)106.71%
Min EPS beat(2)-26.06%
Max EPS beat(2)239.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)-0.84%
Revenue beat(4)2
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)2.52%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)6
Avg Revenue beat(12)-1.43%
Revenue beat(16)8
Avg Revenue beat(16)-1.23%
PT rev (1m)-0.84%
PT rev (3m)-6.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1137.35%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-403.84%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-2.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.16 | ||
| P/S | 3.45 | ||
| P/FCF | 1166.23 | ||
| P/OCF | 526.47 | ||
| P/B | 9.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.9 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.26
Fwd EY4.32%
FCF(TTM)0.01
FCFY0.09%
OCF(TTM)0.01
OCFY0.19%
SpS1.76
BVpS0.63
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROCE | 7.5% | ||
| ROIC | 5.93% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 21.92% | ||
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% | ||
| FCFM | 0.3% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Debt/EBITDA | 6.97 | ||
| Cap/Depr | 23.74% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 6.36% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | -1.51 |
F-Score7
WACC10.89%
ROIC/WACC0.54
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
Revenue Next Year17.78%
Revenue Next 2Y20.45%
Revenue Next 3Y20.92%
Revenue Next 5Y19.94%
EBIT growth 1Y179.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.34%
EBIT Next 3Y110.27%
EBIT Next 5YN/A
FCF growth 1Y101.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.82%
OCF growth 3YN/A
OCF growth 5YN/A